Rifapentine pharmacokinetics in adolescents.

OBJECTIVE Determination of rifapentine pharmacokinetics in healthy adolescent children. DESIGN Prospective Phase II clinical trial. SETTING Clinical research center within a university children's hospital. PATIENTS Twelve subjects ranging in age from 12 to 15 years, male and female. INTERVENTIONS A single oral dose of rifapentine was administered to healthy adolescent volunteers, 450 mg if <45 kg or 600 mg if > or =45 kg. Blood was collected at serial intervals (0, 2, 3, 4, 5, 6, 8, 12, 18, 24, 48 and 72 h postdose). Subjects were observed for adverse effects during the period of study. MEASUREMENTS High pressure liquid chromatography was used to measure the plasma concentration of rifapentine and 25-desacetyl rifapentine in each blood sample. For each subject a plot of mean plasma concentration vs. time data for rifapentine and its metabolite (i.e. 25-desacetyl rifapentine) were created. Subsequently model-independent methods were used to determine the pharmacokinetic profiles for each subject. RESULTS All subjects tolerated rifapentine without adverse effects. The 2-h postdose plasma concentrations of rifapentine (6.59 to 9.05 microg/ml) and 25-desacetyl rifapentine (0.57 to 2.64 microg/ml) far exceeded the MIC of Mycobacterium tuberculosis to rifapentine (approximately 0.12 microg/ml). The combination of a high Cmax (rifapentine, 9.95 to 18.63 microg/ml; 25-desacetyl rifapentine, 3.73 to 7.46 microg/ml) and lengthy terminal elimination phase t1/2 (rifapentine, 10 to 23 h; 25-desacetyl rifapentine, 14 to 35 h) resulted in potentially effective plasma concentrations of both compounds that persisted for at least 48 h in most subjects. CONCLUSIONS A well-tolerated oral rifapentine dose produced rapid and sustained plasma drug concentrations in adolescents that should effectively treat infections caused by M. tuberculosis. Rifapentine pharmacokinetics appears to be similar in adolescent and adult populations.

[1]  R. Owens,et al.  Pharmacokinetics of Rifapentine in Subjects Seropositive for the Human Immunodeficiency Virus: a Phase I Study , 1999, Antimicrobial Agents and Chemotherapy.

[2]  M. Eller,et al.  Disposition and metabolism of 14C-rifapentine in healthy volunteers. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[3]  M. Roussel,et al.  Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[4]  D. Josefson.  FDA approves tuberculosis drug , 1998, BMJ.

[5]  M. Eller,et al.  Pharmacokinetics of Rifapentine in Patients with Varying Degrees of Hepatic Dysfunction , 1998, Journal of clinical pharmacology.

[6]  T. Koudriakova,et al.  Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents , 1997, Clinical pharmacology and therapeutics.

[7]  Nebert Dw.  Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? , 1997, American journal of human genetics.

[8]  J. Leeder.  Developmental Aspects of Drug Metabolism in Children , 1996 .

[9]  M. Reed.  The Ontogeny of Drug Disposition: Focus on Drug Absorption, Distribution, and Excretion* , 1996 .

[10]  T. Blaschke,et al.  Clinical Pharmacokinetics of Rifabutin , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Heifets,et al.  Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages , 1995, Antimicrobial agents and chemotherapy.

[12]  K. Venkatesan.  Pharmacokinetic Drug Interactions with Rifampicin , 1992, Clinical pharmacokinetics.

[13]  D. Mitchison,et al.  In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. , 1987, Tubercle.

[14]  F J Leinweber,et al.  Possible physiological roles of carboxylic ester hydrolases. , 1987, Drug metabolism reviews.

[15]  A. Boobis,et al.  Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. , 1986, British journal of clinical pharmacology.

[16]  H. Nakagawa,et al.  Fundamental studies on the metabolism of rifampicin (RFP). , 1978, Nihon Rai Gakkai zasshi.

[17]  G. Acocella.  Clinical Pharmacokinetics of Rifampicin , 1978, Clinical pharmacokinetics.

[18]  W. Wehrli,et al.  Interaction of rifamycin with bacterial RNA polymerase. , 1968, Proceedings of the National Academy of Sciences of the United States of America.